KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Gains from Sales and Divestitures: 2019-2025

Historic Gains from Sales and Divestitures for Adaptive Biotechnologies (ADPT) over the last 6 years, with Sep 2025 value amounting to $3.2 million.

  • Adaptive Biotechnologies' Gains from Sales and Divestitures rose 31.19% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 31.19%. This contributed to the annual value of $2.6 million for FY2024, which is 71.73% up from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Gains from Sales and Divestitures of $3.2 million as of Q3 2025, which was up 2.35% from $3.1 million recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Gains from Sales and Divestitures peaked at $3.2 million during Q3 2025, and registered a low of $12,500 during Q2 2021.
  • Over the past 3 years, Adaptive Biotechnologies' median Gains from Sales and Divestitures value was $2.3 million (recorded in 2024), while the average stood at $2.2 million.
  • Data for Adaptive Biotechnologies' Gains from Sales and Divestitures shows a peak YoY surged of 1,524.73% (in 2022) over the last 5 years.
  • Adaptive Biotechnologies' Gains from Sales and Divestitures (Quarterly) stood at $18,750 in 2021, then soared by 1,524.73% to $304,637 in 2022, then spiked by 394.64% to $1.5 million in 2023, then surged by 71.73% to $2.6 million in 2024, then spiked by 31.19% to $3.2 million in 2025.
  • Its Gains from Sales and Divestitures stands at $3.2 million for Q3 2025, versus $3.1 million for Q2 2025 and $3.0 million for Q1 2025.